The Age-Related Macular Degeneration (AMD) market is undergoing a transformative phase, fueled by global aging demographics and technological innovations in treatment. Valued at $9.4 billion in 2022, it is projected to reach $15.4 billion by 2032, expanding at a CAGR of 5% over the forecast period.
Understanding AMD: A Growing Vision Crisis
AMD primarily affects individuals over the age of 60, damaging the macula and leading to central vision loss. It’s the leading cause of irreversible blindness in older adults globally.
Two Major Types of AMD:
Dry AMD (Atrophic):
Accounts for 85–90% of cases
Characterized by drusen (yellow deposits) under the retina
Wet AMD (Neovascular):
Less common but responsible for most severe vision loss
Caused by abnormal blood vessel growth beneath the macula
Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/3538
Current Treatment Landscape
Dry AMD:
Managed with AREDS2 formula supplements and lifestyle changes
Wet AMD:
Treated with anti-VEGF injections (e.g., Eylea, Lucentis)
New treatments aim to reduce injection frequency and improve patient compliance
Key Market Growth Drivers
📈 1. Aging Global Population
By 2030: 1 in 6 people will be aged 60 or older (WHO)
By 2050: 426 million people aged 80+, increasing AMD prevalence
💊 2. Rising Demand for Advanced Therapies
Wet AMD affects ~10% of patients, but accounts for the majority of drug usage
Over 10 new drugs in Phase II/III trials for dry AMD
🚀 3. Breakthroughs in Treatment
Roche’s Susvimo: Long-acting implant reducing need for monthly injections
Emerging therapies:
Gene therapy (GT005)
Stem cell treatments (OpRegen)
Mitochondrial-targeted drugs (Elamipretide)
💰 4. Boost in Healthcare Investments
Asia-Pacific: Fastest-growing region due to healthcare reforms and elderly population boom
North America: Market leader with strong pharma presence and adoption of innovative therapies
Market Segmentation Snapshot (2022–2032)
By Drug Type
Aflibercept (Eylea) – Market leader
Ranibizumab (Lucentis) – Widely used for wet AMD
Others – Bevacizumab, Brolucizumab offering cost-effective options
By Disease Type
Wet AMD – Largest share due to high treatment rates
Dry AMD – Growing segment with upcoming drugs like Zimura, ALK-001
By Distribution Channel
Hospital Pharmacies – Dominant due to prescription-only therapies
Retail & Online Pharmacies – Increasing accessibility and patient reach
By Region
North America (40%+ share) – Strong R&D and therapy adoption
Europe – Regulatory support and growing public awareness
Asia-Pacific – Rapid market growth
LAMEA – Emerging potential in underpenetrated markets
Market Challenges
💸 High annual treatment costs (~$5,200 per patient)
⚠️ Limited insurance coverage in low- and middle-income regions
❗ Side effects of anti-VEGF overuse, such as retinal thinning
Competitive Landscape
Leading companies are focused on R&D, strategic collaborations, and expanding drug portfolios:
Regeneron – Eylea
Novartis – Lucentis, Beovu
Roche – Susvimo, Avastin
Bayer – In partnership for Eylea
Apellis Pharmaceuticals – Pegcetacoplan for dry AMD
Future Outlook (2023–2032)
Gene and stem cell therapies may redefine AMD care
AI-powered diagnostics expected to enable earlier detection
Biosimilars and extended-release drugs to improve affordability and adherence
🔍 Key Takeaways
✅ Market Size: $9.4B (2022) → $15.4B (2032) | CAGR 5%
✅ Growth Drivers: Aging population, pipeline drug approvals, wet AMD treatment demand
✅ Popular Therapies: Anti-VEGF injections (Eylea, Lucentis), gene and cell therapies emerging
✅ Leading Players: Regeneron, Roche, Novartis, Bayer, Apellis
✅ Challenges: High cost, insurance gaps, treatment-related side effects
✅ Future Trends: AI diagnostics, regenerative medicine, biosimilars
Enquire Before Buying: https://www.alliedmarketresearch.com/purchase-enquiry/3538
